Four Healthcare Dividends Pay $8,018, but the Risk Is Uneven
A $250,000 split across UnitedHealth, Merck, AbbVie and Pfizer yields about $8,018 annually, but Pfizer supplies nearly 45% of the income and carries the thinnest cushion.
Splitting $250,000 equally across UnitedHealth, Merck, AbbVie and Pfizer would have produced about $8,017.72 in annual dividends at the companies' current payout rates and their October 29 closing prices. That is a 3.21% blended yield. The more important finding is that nearly 45% of the income comes from Pfizer, the company with the highest yield and the least room for a business setback.
The calculation assigns $62,500 to each stock. At the prices used by 24/7 Wall St., UnitedHealth would contribute $1,411.50, Merck $1,452.20, AbbVie $1,564.70 and Pfizer $3,589.32. Those figures are a snapshot, not a promise: yields change with share prices, and boards can change dividends.
UnitedHealth offers the widest earnings cushion
UnitedHealth's 2.26% forward yield is the lowest of the four. A $62,500 position would buy about 152.1 shares and generate roughly $1,411.50 a year at the $2.32 quarterly dividend.
The payout equals about 45% of UnitedHealth's 2026 adjusted earnings forecast of at least $20.50 a share. The company also reported $5.0 billion of share repurchases through the third quarter. That gives management more flexibility than a dividend that absorbs most earnings.
The operating picture is less comfortable. UnitedHealth's medical care ratio improved to 88.4% from 89.9%, but 24/7 Wall St. reported that Medicare Advantage enrollment had fallen by 935,000 since the end of 2025 and noted a Justice Department investigation of the Medicare business. UnitedHealthcare still served 48.3 million medical members. Investors therefore have to weigh strong dividend coverage against pressure in the insurance operation and regulatory uncertainty.
Merck's headline payout ratio needs context
Merck's 2.32% forward yield would generate about $1,452.20 from 427.12 shares. Its $0.85 quarterly dividend, or $3.40 annually, is greater than the company's 2026 adjusted earnings guidance of $2.77 to $2.82 a share. On the surface, that looks unsustainable.
The comparison is distorted by $6.05 a share of one-time charges tied to the Cidara, Terns and SciBrunch transactions. Merck reported third-quarter adjusted earnings of $2.49 a share, while Keytruda sales reached $8.60 billion. It is still funding late-stage programs including sac-TMT and a cancer vaccine with Moderna. The more durable threat is generic pressure on products such as Bridion and Januvia, not the acquisition charges alone.
AbbVie's raise is backed by its newer drugs
AbbVie would provide about $1,564.70 of annual income from 214.93 shares, based on a 2.50% forward yield. Its board raised the quarterly dividend 5.2%, from $1.73 to $1.82, with the new rate payable February 16, 2027. The $7.28 annual payout equals about 52% of AbbVie's adjusted earnings guidance of $13.95 to $13.99 a share.
The business is replacing Humira faster than the old blockbuster is shrinking. Third-quarter Skyrizi revenue rose 22.7% to $5.78 billion and Rinvoq grew 23.9%, while Humira revenue fell 31.2% as biosimilars took share. That product transition, rather than the company's dividend history by itself, is what supports the latest increase.
Pfizer supplies the income and most of the risk
Pfizer's 5.74% forward yield produces about $3,589.32 from 2,086.81 shares, more than the combined income from UnitedHealth and Merck. The $0.43 quarterly dividend has remained unchanged since early 2025, however, and its $1.72 annual rate uses roughly 59% of Pfizer's adjusted earnings guidance of $2.80 to $3.00 a share.
Second-quarter adjusted earnings were $0.77 a share, but Paxlovid revenue fell 95% on an operational basis. Pfizer expects generic and biosimilar competition to reduce 2026 revenue by about $1.1 billion. It completed no repurchases in the first half, and its current guidance assumes none for the full year. The next $0.43 dividend is due December 7 to holders of record on November 6.
The portfolio reaches its $8,017.72 income estimate, but the total conceals very different risks. UnitedHealth has the lowest yield and the strongest earnings coverage. AbbVie offers the freshest increase and evidence that its newer drugs are replacing Humira. Merck's annual payout looks uncovered only because deal charges depress current guidance. Pfizer delivers the most cash today, while its flat dividend, patent erosion and post-pandemic sales decline leave the least margin for disappointment.